Tianxin Pharmaceutical released its 2026 interim report. During the reporting period, total operating revenue was 1.309 billion yuan, and net profit attributable to the parent company was 319 million yuan, a decrease of 36.6888 million yuan compared with the same period last year, down 10.31% year-on-year. Net cash inflow from operating activities was 384 million yuan, the asset-liability ratio was 22.43%, the gross margin was 41.07%, and diluted earnings per share was 0.73 yuan, down 10.98% year-on-year. The number of shareholders was 11,400, and the top ten shareholders held 91.19% of the total share capital.
JiangXi Tianxin Pharm Co LtdNet profit fell 10.31% year-on-year in the interim report.
